Neuroderm Ltd (NDRM) Working Against Surgery Intervention In Parkinson’s Disease
Neuroderm Ltd (NASDAQ:NDRM) recently reported that its drug candidate for Parkinson’s disease showed positive results in a mid-stage trial. The company intends to take the investigational drug through other trials to obtain regulatory approval for commercialization in the U.S., Europe and other markets.
The drug was tried in 16 patients in two versions known as ND0612H and ND0612L. High doses were found to be effective in patients with a server form of the disease. The development offers hope for an alternative therapy for Parkinson’s disease, which currently requires surgery.
Reducing need for surgery
Although surgery has mostly been used to correct Parkinson’s disease, the market requires a simpler and even more effective treatment. Such is expected to help in avoiding the need of intervention through surgery to address advanced conditions of the disease, which is good needs for patients because of the potential complications with surgeries and the costs involved.
The positive data from mid-stage trial is expected to support continued development of the drug in the U.S. and EU in 2015. Neuroderm Ltd (NASDAQ:NDRM) intends to push forward with the development of the two versions of the drug, ND0612H and ND0612L, in the two markets.
The market for Parkinson’s treatment is huge, given that more than 1 million people in America suffer from the condition. Perhaps the big revenue opportunity in the market explains why Neuroderm Ltd (NASDAQ:NDRM) is also testing another drug targeting Parkinson’s disease. Neuroderm’s rich pipeline also includes drugs designed for conditions that include schizophrenia and Alzheimer’s disease.
There appear to be several reasons to keep Neuroderm Ltd (NASDAQ:NDRM) in the watch-list. The company’s successful mid-stage Parkinson’s drug trial and the fact that it has additional candidate for the same condition suggest higher success chance in the market. Additionally, focus on other diseases with unmet medical needs such as Alzheimer’s disease also inspires hope in the stock.
Neuroderm Ltd (NASDAQ:NDRM) cash position deteriorated to $1.63 million in the latest quarter from $3.12 million in the previous quarter.